Roth et al., 2022 - Google Patents
Optimised non-coding regions of mRNA SARS-CoV-2 vaccine CV2CoV improves homologous and heterologous neutralising antibody responsesRoth et al., 2022
View HTML- Document ID
- 3960447190622157637
- Author
- Roth N
- Schön J
- Hoffmann D
- Thran M
- Thess A
- Mueller S
- Petsch B
- Rauch S
- Publication year
- Publication venue
- Vaccines
External Links
Snippet
More than two years after the emergence of SARS-CoV-2, 33 COVID-19 vaccines, based on different platforms, have been approved in 197 countries. Novel variants that are less efficiently neutralised by antibodies raised against ancestral SARS-CoV-2 are circulating …
- 229960005486 vaccines 0 title abstract description 61
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/01—Social networking
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kanokudom et al. | Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine | |
| Kim et al. | A novel synonymous mutation of SARS-CoV-2: is this possible to affect their antigenicity and immunogenicity? | |
| Lippi et al. | Anti-SARS-CoV-2 antibodies testing in recipients of COVID-19 vaccination: why, when, and how? | |
| Khong et al. | Antibody response of combination of BNT162b2 and CoronaVac platforms of COVID-19 vaccines against Omicron variant | |
| Lapa et al. | Retention of neutralizing response against SARS-CoV-2 omicron variant in sputnik V-Vaccinated individuals | |
| Prescott et al. | Long-term single-dose efficacy of a vesicular stomatitis virus-based Andes virus vaccine in Syrian hamsters | |
| Roth et al. | Optimised non-coding regions of mRNA SARS-CoV-2 vaccine CV2CoV improves homologous and heterologous neutralising antibody responses | |
| Guzmán-Martínez et al. | IgG antibodies generation and side effects caused by Ad5-nCoV vaccine (CanSino Biologics) and BNT162b2 vaccine (Pfizer/BioNTech) among Mexican population | |
| Cheng et al. | Immunogenicity and safety of homologous and heterologous prime–boost immunization with COVID-19 vaccine: systematic review and meta-analysis | |
| Yang et al. | SARS-CoV-2 variants, RBD mutations, binding affinity, and antibody escape | |
| Anichini et al. | Neutralizing antibody response of vaccinees to SARS-CoV-2 variants | |
| Skrzat-Klapaczyńska et al. | The beneficial effect of the COVID-19 vaccine booster dose among healthcare workers in an infectious diseases center | |
| Li et al. | Rational design of a pan-coronavirus vaccine based on conserved CTL epitopes | |
| Tsilibary et al. | Vaccines for influenza | |
| Khurana | Development and regulation of novel influenza virus vaccines: a United States young scientist perspective | |
| Lin et al. | Tag-free SARS-CoV-2 receptor binding domain (RBD), but not C-terminal tagged SARS-CoV-2 RBD, induces a rapid and potent neutralizing antibody response | |
| Salvaggio et al. | Antibody response after BNT162b2 vaccination in healthcare workers previously exposed and not exposed to SARS-CoV-2 | |
| Łusiak-Szelachowska et al. | Do anti-phage antibodies persist after phage therapy? A Preliminary Report | |
| Muñoz-Valle et al. | Efficacy and safety of heterologous booster vaccination after Ad5-nCoV (CanSino Biologics) vaccine: a preliminary descriptive study | |
| Abdelhafiz et al. | Sinopharm’s BBIBP-CorV vaccine and ChAdOx1 nCoV-19 vaccine are associated with a comparable immune response against SARS-CoV-2 | |
| Cianci et al. | Efforts to Improve the Seasonal Influenza Vaccine | |
| Ravlo et al. | Antiviral immunoglobulins of chicken egg yolk for potential prevention of SARS-CoV-2 infection | |
| Mahmoud et al. | Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3. 4.4 b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses | |
| Guzmán | Next generation influenza vaccines: looking into the crystal ball | |
| Mollura et al. | Antibody titer correlates with omicron infection in vaccinated healthcare workers |